NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) Announces FDA Qualified Infectious Disease Product (QIDP) and Fast Track Designation of NRX-101 in Complicated Urinary Tract Infection and Pyelonephritis ...Middle East

NRX-101 has demonstrated potent activity against resistant urinary pathogens upon FDA review QIDP designation grants Priority Review and an additional 5 years of additional product exclusivity 3 million Americans develop complicated Urinary Tract Infection (cUTI) each year at a cost that...

Hence then, the article about nrx pharmaceuticals inc nasdaq nrxp announces fda qualified infectious disease product qidp and fast track designation of nrx 101 in complicated urinary tract infection and pyelonephritis was published today ( Tuesday 16/01/2024 - 02:57 PM ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) Announces FDA Qualified Infectious Disease Product (QIDP) and Fast Track Designation of NRX-101 in Complicated Urinary Tract Infection and Pyelonephritis )

Also on site :

• Comcast Stock Pops on NBCUniversal Spin-Off as Wall Street Waves Farewell to Vertical Integration
• Supreme Court allows states to count mail-in ballots that arrive late, rejecting RNC challenge
• Employee shot, killed in parking lot of suburban Chicago Amazon facility; lockdown in effect